Advertisement

AAPS PharmSciTech

, Volume 15, Issue 5, pp 1138–1148 | Cite as

A New Lipid-Based Nano Formulation of Vinorelbine

  • Fatemeh Bahadori
  • Gülaçtı Topçu
  • Mehmet S. Eroğlu
  • Hayat Önyüksel
Research Article

Abstract

Vinorelbine (VLB) is a semi-synthetic Vinca alkaloid which is currently used in treatment of different cancer types mainly advanced breast cancer (ABC) and advanced/metastatic non-small cell lung cancer (NSCLC). However, its marketed formulation has been reported to have serious side effects, such as granulocytopenia, which is the major dose-limiting toxicity. Other unwanted effects include venous discoloration and phlebitis proximal to the site of injection, as well as localized rashes and urticaria, blistering, and skin sloughing. Our long-term aim in synthesizing a novel nanomicellar vinorelbine formulation is to reduce or even eliminate these side effects and increase drug activity by formulating the drug in a lipid-based system as a nanomedicine targeted to the site of action. To this end, the purpose of this study was to prepare, characterize, and determine the in vitro efficacy of vinorelbine-loaded sterically stabilized, biocompatible, and biodegradable phospholipid nanomicelles (SSM; size, ∼15 nm). Our results indicated that vinorelbine incorporate at high quantities and within the interface between the core and palisade sections of the micelles. Incorporation ratio of drug within sterically stabilized micelles increased as the total amount of drug in the system increased, and no drug particles were formed at the highest drug concentrations tested. The nanomicellar formulation of vinorelbine was ∼6.7-fold more potent than vinorelbine dissolved in DMSO on MCF-7 cell line. Collectively, these data indicate that vinorelbine-loaded SSM can be developed as a new, safe, stable, and effective nanomedicine for the treatment of breast and lung cancers.

KEY WORDS

DSPE-PEG 2000 nano drug delivery sterically stabilized micelles targeted drug delivery vinorelbine 

Notes

ACKNOWLEDGMENTS

This study was supported, in part, by NIH grant CA121797. Most part of this investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number CO6RR15482 from the National Center for Research Resources, NIH. Also, the authors would like to thank Dr. Antonina Kuzmis for her very precious advices and assistance during the experimentations.

REFERENCES

  1. 1.
    Krikorian A, Breillout F. Vinorelbine (Navelbine ® 1). A new semisynthetic Vinca alkaloid. Onkologie. 1991;4:7–12.CrossRefGoogle Scholar
  2. 2.
    Zhou XJ, Placidi M, Rahmani R. Uptake and metabolism of Vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res. 1994;14(3A):1017–22.PubMedGoogle Scholar
  3. 3.
    Etievant C, Barret JM, Kruczynski A, Perrin D, Hill BT. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Investig New Drugs. 1998;16(1):3–17.CrossRefGoogle Scholar
  4. 4.
    Duflos A, Jacquesy JC, Kruczynski A, Etievant C, Barret JM, Hill BT, et al. Extending the scope of Vinca alkaloids with superacid chemistry. Clin Cancer Res. 1999;5:3794S-S.Google Scholar
  5. 5.
    Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev. 1996;22(2):127–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Koukoulitsa C, Kyrikou I, Demetzos C, Mavromoustakos T. The role of the anticancer drug vinorelbine in lipid bilayers using differential scanning calorimetry and molecular modeling. Chem Phys Lipids. 2006;144(1):85–95.PubMedCrossRefGoogle Scholar
  7. 7.
    Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1–2):72–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Semple SC, Leone R, Wang J, Leng EC, Klimuk SK, Eisenhardt ML, et al. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci. 2005;94(5):1024–38.PubMedCrossRefGoogle Scholar
  9. 9.
    Toso C, Lindley C. Vinorelbine: a novel Vinca alkaloid. Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm. 1995;52(12):1287–304. quizz 340–1.Google Scholar
  10. 10.
    Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, et al. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. Lung Cancer. 2007;55(3):337–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Li C, Cui J, Wang C, Zhang L, Xiu X, Li Y, et al. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies. J Pharm Pharmacol. 2011;63(3):376–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Drummond DC, Noble CO, Guo Z, Hayes ME, Park JW, Ou CJ, et al. Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J Pharmacol Exp Ther. 2009;328(1):321–30.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–92.PubMedGoogle Scholar
  14. 14.
    Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther. 2003;2(5):427–36.PubMedGoogle Scholar
  15. 15.
    Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18(4):259–96.PubMedCrossRefGoogle Scholar
  16. 16.
    Georgiadis MS, Russell EK, Gazdar AF, Johnson BE. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res. 1997;3(3):449–54.PubMedGoogle Scholar
  17. 17.
    Horton JK, Houghton PJ, Houghton JA. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human-tumor xenografts. Biochem Pharmacol. 1988;37(20):3995–4000.PubMedCrossRefGoogle Scholar
  18. 18.
    Burris HA, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, et al. Activity of topotecan, a new topoisomerase-I inhibitor, against human tumor colony-forming-units in vitro. J Natl Cancer Inst. 1992;84(23):1816–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. Phase I clinical and pharmacokinetic study of PK1 N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin: first member of a new class of chemotherapeutic agents—drug-polymer conjugates. Clin Cancer Res. 1999;5(1):83–94.PubMedGoogle Scholar
  20. 20.
    Drummond DC, Meyer O, Hong KL, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51(4):691–743.PubMedGoogle Scholar
  21. 21.
    Krishnadas A, Rubinstein I, Onyuksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm Res. 2003;20(2):297–302.PubMedCrossRefGoogle Scholar
  22. 22.
    Onyuksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 2009;274(2):327–30.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Dagar A, Kuzmis A, Rubinstein I, Sekosan M, Onyuksel H. VIP-targeted cytotoxic nanomedicine for breast cancer. Drug Deliv Transl Res. 2012;2(6):454–62.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release. 2003;91(1–2):123–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Sethi V, Rubinstein I, Kuzmis A, Kastrissios H, Artwohl J, Onyuksel H. Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. Mol Pharm. 2013;10(2):728–38.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Ashok B, Arleth L, Hjelm RP, Rubinstein I, Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci. 2004;93(10):2476–87.PubMedCrossRefGoogle Scholar
  27. 27.
    Lim SB, Rubinstein I, Onyuksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles. Int J Pharm. 2008;356(1–2):345–50.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 2012;7(6):383–8.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Onyuksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm. 2009;365(1–2):157–61.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Vukovic L, Khatib FA, Drake SP, Madriaga A, Brandenburg KS, Kral P, et al. Structure and dynamics of highly PEG-ylated sterically stabilized micelles in aqueous media. J Am Chem Soc. 2011;133(34):13481–8.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Banerjee A, Onyuksel H. Human pancreatic polypeptide in a phospholipid-based micellar formulation. Pharm Res. 2012;29(6):1698–711.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Markovsky E, Koroukhov N, Golomb G. Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomedicine. 2007;2(4):545–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Debal V, Morjani H, Millot JM, Angiboust JF, Gourdier B, Manfait M. Determination of vinorelbine (Navelbine) in tumor-cells by high-performance liquid-chromatography. J Chromatogr Biomed Appl. 1992;581(1):93–9.CrossRefGoogle Scholar
  34. 34.
    Jehl F, Debs J, Herlin C, Quoix E, Gallion C, Monteil H. Determination of navelbine and desacetylnavelbine in biological fluids by high-performance liquid chromatography. J Chromatogr. 1990;525(1):225–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Cho YW, Lee J, Lee SC, Huh KM, Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release. 2004;97(2):249–57.PubMedCrossRefGoogle Scholar
  36. 36.
    Michalowski CB, Guterres SS, Dalla Costa T. Microdialysis for evaluating the entrapment and release of a lipophilic drug from nanoparticles. J Pharm Biomed Anal. 2004;35(5):1093–100.PubMedCrossRefGoogle Scholar
  37. 37.
    Allahverdiyev A, Duran N, Ozguven M, Koltas S. Antiviral activity of the volatile oils of Melissa officinalis L. against Herpes simplex virus type-2. Phytomedicine. 2004;11(7–8):657–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Davydov M, Volkov S, Polotsky B, Gerasimov S, Machaladze Z, Allahverdiyev A, et al. Mediastinal lymphadenectomy improves survival in surgically treated patients with non-small cell lung cancer. Int J Cancer. 2002;414–5.Google Scholar
  39. 39.
    Sugin Z, Yuksel N, Baykara T. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur J Pharm Biopharm. 2006;64(3):261–8.CrossRefGoogle Scholar
  40. 40.
    Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73(2–3):137–72.PubMedCrossRefGoogle Scholar
  41. 41.
    Cesur H, Rubinstein I, Pai A, Onyuksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine. 2009;5(2):178–83.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Koo OM, Rubinstein I, Onyuksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res. 2011;28(4):776–87.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Lv Q, Yu A, Xi Y, Li H, Song Z, Cui J, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009;372(1–2):191–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Sullivan CO, Birkinshaw C. In vitro degradation of insulin-loaded poly (n-butylcyanoacrylate) nanoparticles. Biomaterials. 2004;25(18):4375–82.PubMedCrossRefGoogle Scholar
  45. 45.
    Holdgate GA, Ward WHJ. Measurements of binding thermodynamics in drug discovery. Drug Discov Today. 2005;10(22):1543–50.PubMedCrossRefGoogle Scholar
  46. 46.
    Kastantin M, Ananthanarayanan B, Karmali P, Ruoslahti E, Tirrell M. Effect of the lipid chain melting transition on the stability of DSPE-PEG (2000) micelles. Langmuir. 2009;25(13):7279–86.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Maswadeh H, Demetzos C, Daliani I, Kyrikou I, Mavromoustakos T, Tsortos A, et al. A molecular basis explanation of the dynamic and thermal effects of vinblastine sulfate upon dipalmitoylphosphatidylcholine bilayer membranes. Biochim Biophys Acta-Biomembr. 2002;1567(1–2):49–55.CrossRefGoogle Scholar
  48. 48.
    Liu XM, Wang LG, Kreis W, Budman DR, Adams LM. Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. Br J Cancer. 2001;85:1403–11.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, Magee WE. Amphotericin-B in liposomes—a novel therapy for histoplasmosis. Am Rev Respir Dis. 1982;125(5):610–1.PubMedGoogle Scholar
  50. 50.
    Rex S, Zuckermann MJ, Lafleur M, Silvius JR. Experimental and Monte Carlo simulation studies of the thermodynamics of polyethyleneglycol chains grafted to lipid bilayers. Biophys J. 1998;75(6):2900–14.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Rubinstein I, Soos I, Onyuksel H. Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells. Chem Biol Interact. 2008;171(2):190–4.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2014

Authors and Affiliations

  • Fatemeh Bahadori
    • 1
    • 2
    • 3
  • Gülaçtı Topçu
    • 2
    • 3
  • Mehmet S. Eroğlu
    • 4
    • 5
  • Hayat Önyüksel
    • 1
  1. 1.Department of Biopharmaceutical Sciences (M/C 865), College of PharmacyUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Department of Chemistry, Faculty of Science and LettersIstanbul Technical UniversityMaslakTurkey
  3. 3.Department of Pharmaceutical Biotechnology, Faculty of PharmacyBezmialem Vakif UniversityFatihTurkey
  4. 4.Engineering Faculty, Department of Chemical EngineeringMarmara UniversityKadikoyTurkey
  5. 5.Chemistry Group LaboratoriesTUBITAK-UMEGebzeTurkey

Personalised recommendations